|
Can we succeed at drug discovery? |
|
Written by The Economic Times
|
|
Wednesday, 12 February 2003 |
|
The Economic Times There are two facets of basic research in the pharma industry: new drug discovery and development research and developing new, cost-effective production processes for manufacture of new drugs. Indian pharma companies have already excelled in process innovation and technology and are able to produce practically all the drugs needed for health care programmes, at affordable prices. Indian pharma companies have set up state-of-the-art NDDR centres. In the short time these centres have been in existence, they have a number of new drugs in the pipe-line, many of which without doubt will be approved and marketed in due course. A new drug introduction by the best companies in the world takes 10-15 years and the same will happen for the drugs discovered by Indian pharma companies. |
|
Read more...
|
|
|
Have some sympathy, Mr Sinha |
|
Written by The Indian EXPRESS
|
|
Friday, 15 March 2002 |
|
Friday, March 15, 2002
Have some sympathy, Mr Sinha Budgeting nightmares for cancer patients
HARINDER S. SIKKA
Year after year, the annual budget is presented in Parliament with great fanfare but the real picture emerges only after the fine print’s hidden truth sinks in. This year’s budget is no different. In fact, it is worse when it comes to patients suffering from life-threatening diseases. |
|
Read more...
|
|
|
India can be a super power in pharma R&D |
|
Written by THE ECONOMIC TIMES
|
|
Thursday, 28 September 2000 |
|
THE ECONOMIC TIMES 28 September 2000 India can be a super power in pharma R&D
HARINDER SIKKA
Even a casual reading of our Shastras and Vedas would confirm the in-depth knowledge acquired through R&D by our scientists thousands of years ago, especially in the area of biotechnology. One of the major differences of yesteryear research was that it was proactive to general masses. Whereas today's research is mainly proactive to customer, not necessarily from the lowest strata of the society. Today's R&D revolve around the existing rules of the market, i.e., what products to sell, at what price and to whom.
|
|
Read more...
|
|
|
Photograph in Pharma Dialogue |
|
Written by Pharma Dialogue
|
|
|
|
Photograph in Pharma Dialogue Click on Read more to view.... |
|
Read more...
|
|
|
Written by LiveMint.com
|
|
|
Attention, Mr Ramadoss The fight over Paul Wolfowitz had little to do with his girl friend and everything to do with his anti-corruption efforts. That truth is now coming into sharper relief, as a showdown looms over a series of reports about, and by, the Bank's anti-corruption unit. Senior World Bank officials are eager to discredit a forthcoming internal report on corruption in a major Bank-supported healthcare project in India. |
|
Read more...
|
|
|
<< Start < Prev 1 2 3 Next > End >>
|
| Results 19 - 23 of 23 |
